Supplementary
. Western blot analysis of TbMCU-GFP, growth of TbMCU-GFP transfectants, basal Ca 2+ accumulation in RNAi PCF trypanosomes, and inhibition of the mitochondrial membrane potential of BSF trypanosomes by oligomycin. (a) Western blot analysis of TbMCU-GFP expressed in PCF trypanosomes. Lysates containing 30 µg of protein from PCF trypanosomes were subjected to SDSpolyacrylamide gel electrophoresis on 10% polyacrylamide gels and transferred to a nitrocellulose membrane. The blot was probed with antibodies against GFP as described under Methods. Two bands of ~57/62 kDa were detected in PCF homogenates. Migration of molecular mass standards is shown to the left of the gels. Bottom: membrane was stripped and re-incubated with anti-tubulin antibody as a loading control. (b) Growth of wild type (black lines) and TbMCU-GFP (red lines) transfectants. (c and d) Quantification of basal Rhod-2 (mitochondrial) (c) and Fluo-4 (cytosolic) (d) fluorescence in control PCF trypanosomes (-Tet) and TbMCU silenced PCF trypanosomes (+Tet). Basal Rhod-2 and Fluo-4 fluorescence of PCF trypanosomes (5 x 10 7 cells) were measured in a fluorometer. The results are means ± SD (n = 3). **Differences are statistically significant p < 0.05; ns, not significant, Student's t test. (e) Addition of oligomycin (Oligo, 2.5 µg/ml) collapses the mitochondrial membrane potential in both -Tet and +Tet BSF TbMCU RNAi trypanosomes. Other conditions as in Fig. 3c . ] TbMCU allele knockout. Primer 1 was designed to bind inside the 5' recombination site and primer 2 binds 145 bp downstream of the 3' recombination site. Primers 3 and 4 bind within the phleomycin (PLEO) resistance gene. Primers 5 and 6 were designed to bind inside the recombinant ribosomal DNA loci, whose entire intergenic region on the chromosome is about 10 kb. Primers 7 and 8 were designed 160 bp upstream and 263 bp downstream of the ectopic TbMCU-HA based on the expression vector pLew100v5-bsd, respectively. Primers 9 and 10 bind to the 5'-and 3'-termini of TbMCU ORF, respectively. Primers 11 and 12 bind within the puromycin (PURO) resistance gene. BLAST, blasticidin resistance gene. Primers used (Supplementary Table S1 ) and expected sizes of PCR products are shown. 

Supplementary Methods
Chemicals and reagents. TRIzol reagent, Calcium Green-5N, Rhod-2 AM, Mito-Tracker Red, Fluo-4 AM, Fluronic F-127, MitoSOX Red, rabbit polyclonal antibody against GFP, Alexa-conjugated secondary antibodies, and ATP determination kit were purchased from Invitrogen. Pfu Ultra HF DNA polymerase was purchased from Agilent. The expression vector pET32 EK/Lic was purchased from Novagen. [-
32 P]dCTP (3,000 Ci/mmol) was from Perkin Elmer. E. coli OverExpress C43 (DE3) strain was purchased from Lucigen. Purified HA.11 clone 16B12 monoclonal antibody against HA was purchased from Covance. The enhanced chemiluminescence (ECL) detection kit was from Amersham Biosciences (GE Healthcare Life Sciences). Pierce ECL Western blotting substrate was from Thermo Fisher Scientific. The protein assay reagent, Precision Plus WesternC standards, ZetaProbe GT Genomic Testing blotting and nitrocellulose membranes were from Bio-Rad. AMAXA Human T-cell Nucleofector kit was purchased from Lonza. Prime-a Gene Labeling System was from Promega. QIAquick gel extraction kit and MinElute PCR purification kit, Ni-NTA agarose, and Protein G Agarose Resins were from QIAGEN. Complete, EDTA-free protease inhibitor cocktail tablets were purchased from Roche Applied Science. The primers were purchased from Integrated DNA Technologies. All other reagents of analytical grade were from Sigma.
Cell transfections. Mid-log phase PCF (~5  10 6 cells/ml) were harvested by centrifugation at 1,000 g for 7 min, washed with Cytomix buffer (2 mM EGTA, 3 mM MgCl 2 , 120 mM KCl, 0.5% glucose, 0.15 mM CaCl 2 , 0.1 mg/ml BSA, 10 mM K 2 HPO 4 /KH 2 PO 4 , 1 mM hypoxanthine, 25 mM Hepes, pH 7.6) and resuspended in 0.45 ml of the same buffer at a cell density of 2.5  10 7 cells/ml. The washed cells were mixed with 50 µl of NotIlinearized plasmid DNA (10 g) in a 0.4-cm electroporation cuvette and subjected to two pulses from a Bio-Rad Gene Pulser electroporator set at 1.5 kv and 25 µF. The stable transformants were obtained in SDM-79 medium supplemented with 15% FBS plus the appropriate antibiotic (5 g/ml phleomycin, 10 g/ml blasticidin, 15 g/ml G418 and/or 50 g/ml hygromycin). For the BSF, 10 µg of NotI-linearized plasmid DNA, purified resistance gene cassettes, or PCR product (<10 µl) was used per 4 x 10 7 mid-log phase cells in 100 µl AMAXA Human Tcell Nucleofector solution. Electroporation was performed using 2 mm gap cuvettes with program X-001 of the AMAXA Nucleofector. Following each transfection, soluble transformants were selected and cloned by limiting dilution in HMI-9 medium containing 15% FBS with appropriate antibiotics (2.5 µg/ml phleomycin, 2.5 µg/ml G418, 5 µg/ml blasticidin, 0.1 µg/ml puromycin) in 24-well plates. Antibiotic-resistant clones were further characterized as described below. Overexpression, RNAi and conditional knockout mutants of TbMCU were induced or maintained with 1 µg/ml fresh tetracycline when the cells were at a density of 2 x 10 6 PCF or 1 x 10 5 BSF cells/ml. Overexpression, RNAi and conditional knockout mutants of TbMCU were induced or maintained with 1 µg/ml fresh tetracycline when the cells were at a density of 2 x 10 6 PCF or 1 x 10 5 BSF cells/ml. In
